Clinical Trial Update: Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 study evaluated neoadjuvant MEDI4736 (durvalumab) with weekly nab-paclitaxel and dose-dense AC in Stage I-III triple-negative breast cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• AC
• MEDI4736 (Durvalumab)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Yale University | Conditions: Breast Neoplasms | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-10-26